Obesity Management Market Size To Expand at a Notable CAGR Of 9.20% During 2022 - 2030

Pune, India, 2022 /MRFR Press Release/- Market Research Future has a half cooked research report on Global Obesity Management Market.

Market Synopsis

Market Research Future (MRFR) speculates that the Obesity Management Market is anticipated to reach USD 268.70 billion by 2030 at a 9.20 % CAGR during the forecast period 2022-2030. Unhealthy eating habits and changing lifestyle are the major factors favoring the market growth. Obesity is referred to as the illness in an individual’s body in which the body gains excessive fat and adversely affects the health and results in diabetes, hypertension, and heart disease. Obesity management comprises services, products, and therapies which helps to reduce and manage weight in patients suffering from obesity.

Market Potential and Pitfalls

With unhealthy eating habits and changing lifestyle, the prevalence of obesity is increasing, thereby fostering the market growth across the world. Drug manufacturers are heavily investing in R&D activities in order to develop anti-obesity drugs, thereby influencing the obesity management market to a great extent. Moreover, healthcare solution providers are developing innovative solutions for the healthcare sector. Hospitals are offering surgery options as per the condition and medical history of the patient. Such factors are driving the market growth to a great extent. Growing patient population coupled with the R&D activities by the market giants are highly favoring the market growth. For instance, researchers of the University of Liverpool had introduced a treatment for obesity back in 2015. Factors such as rising initiatives by the market players in collaboration with the government in order to generate awareness regarding the negative impact of obesity on health are predicted to propel the market growth. Additional factors such as increasing awareness of weight management techniques are considered to influence the market growth in the coming years. Moreover, with increasing working population coupled with the growth in nuclear families, the demand for inexpensive, fast food and takeaway meals have increased, thereby triggering the obesity management market throughout the forecast period.

On the contrary, the high availability of low-cost alternatives, the high cost of customization, and post-surgical side effects are considered some of the top barriers likely to disrupt the market growth throughout the appraisal period.

Global Obesity Management Market: Segmental Analysis

The global obesity management market has been segmented on the basis of prescription, surgery, and lifestyle changes.

By mode of prescription, the obesity management market has been segmented into orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), bupropion and naltrexone (Contrave), liraglutide (Saxenda), and others.

By mode of surgery, the obesity management market has been segmented into gastric bypass surgery, laparoscopic adjustable gastric banding (LAGB), biliopancreatic diversion with duodenal switch, and others. Among these, the gastric bypass surgery segment is estimated to be the fastest growing market owing to faster recovery time, improved psychological status, and improved longevity.

By mode of lifestyle changes, the global obesity management market has been segmented into dietary changes, exercise, and others.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Obesity Management Market Research Report

Regional Insights

Geographically, the obesity management market spans across regions namely, Europe, North America, Asia Pacific, and Rest-of-the-World (RoW).

Among all the regions, Asia Pacific is considered to expand at a rapid pace and is estimated to retain its dominance. The growth is credited to the lack of physical activity, unhealthy life balance, and poor diet. Moreover, the government is highly focusing on the latest technologies and advanced treatment, which is further initiating R&D activities for the development of new drugs. In this region, China and India are extensively focusing on the market players owing to the increasing purchasing power coupled with a huge patient pool as compared to other economies.

The North American region is likely to project as the largest market for obesity management owing to the presence of an obese population along with advanced treatment options. For instance, as per the CDC, approximately 37.9% of the adults were suffering from obesity from 2013 to 2014. Around 70.7% of the adult population were suffering from overweight.

Industry Updates

February 13, 2019: GI Dynamics Inc., a medical device company developing EndoBarrier for patients suffering from obesity and type 2 diabetes, has recently announced that they have received the Institutional Review Board (IRB) approval in order to conduct its pivotal trial of EndoBarrier.

Competitive Dashboard

The prominent players operating the global obesity management market are Merck Sharp & Dohme Corp. a subsidiary of Merck & Co. Inc. (US), Pfizer Inc. (US), Ethicon Inc. (U.S.), AstraZeneca (UK), Apollo Endosurgery (U.S.), Herbalife Ltd. (U.S.), and F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline Plc. (UK).